| 77.97 0 (0%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 121.73  |
1-year : | 141.35 |
| Resists | First : | 104.22 |
Second : | 121.01 |
| Pivot price | 91.22 |
|||
| Supports | First : | 77.05 |
Second : | 64.11 |
| MAs | MA(5) : | 79.86 |
MA(20) : | 96.64 |
| MA(100) : | 92.83 |
MA(250) : | 77.95 |
|
| MACD | MACD : | -8.6 |
Signal : | -6.5 |
| %K %D | K(14,3) : | 1.6 |
D(3) : | 1.5 |
| RSI | RSI(14): 20.1 | |||
| 52-week | High : | 124.81 | Low : | 50.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MNPR ] has closed above bottom band by 16.7%. Bollinger Bands are 77.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 80.19 - 80.72 | 80.72 - 81.2 |
| Low: | 75.76 - 76.43 | 76.43 - 77.04 |
| Close: | 76.94 - 77.99 | 77.99 - 78.94 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Thu, 01 Oct 2026
16,800 shares are proposed for sale by Monopar Therapeutics (MNPR) director Christopher Starr. - Stock Titan
Mon, 28 Sep 2026
Four share sales at $87.15 to $89.79: Monopar Therapeutics (MNPR) CEO also exercised options. - Stock Titan
Wed, 23 Sep 2026
Monopar Therapeutics stock trades on a clinical pipeline catalyst - AD HOC NEWS
Mon, 24 Aug 2026
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - Simply Wall Street
Thu, 13 Aug 2026
Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ) - Seeking Alpha
Thu, 23 Jul 2026
Monopar Advances Wilson Disease Therapy to FDA - allsci.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 23.3 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 887 (K) |
| Shares Short P.Month | 1,360 (K) |
| EPS | -2.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | -19.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -35.61 |
| PEG Ratio | 0 |
| Price to Book value | 3.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -42.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|